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Abstract
Background: This study aimed to investigate medical doctors’ awareness of bisphosphonate-related osteonecrosis
of the jaw (BRONJ) and the status of dental referrals.
Methods: Self-administered questionnaires were distributed to medical doctors practicing internal medicine, family
medicine, and orthopedics at the 6 tertiary medical centers located in Seoul, Korea. The survey consisted of 22
questions regarding the general characteristics, bisphosphonate therapy, awareness of BRONJ, and implementation
of dental referrals.
Results: Among 192 medical doctors, 21.9 % had not heard of the disease. Only 8.9 % correctly answered all 5 questions
testing BRONJ knowledge. Dental referrals made by medical doctors were implemented in less than 30 % of the
total patients. Oncology specialists most often recognized the necessity of dental referrals followed in decreasing
order by endocrinology, rheumatology, family medicine, and orthopedic specialists.
Conclusion: Given medical doctors’ low BRONJ perception and implementation level of dental referrals, enhancing
information dissemination on BRONJ and development of a highly accessible educational program recognizing the
need for dental referrals are urgent.
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Abbreviations: AAOMS, American Association of Oral and Maxillofacial Surgeons; BP, Bisphosphonates;
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Background
Bisphosphonates (BP) are a class of drugs used in the
treatment and prevention of various bone diseases, such
as osteoporosis, osteitis deformans, multiple myeloma,
osteogenesis imperfecta, and bone metastases, by sup-
pressing osteoclast-mediated bone resorption through
apoptosis of osteoclasts [1]. Due to the drug’s safety and
strong bone-specific inhibitory effect on osteoclastic ac-
tivity, BPs have effectively been used for decades [2, 3].
However, in the recent years, there has been a serious
adverse effect of jaw necrosis associated with the admin-
istration of BPs [4, 5]. Although the pathophysiology of
jaw necrosis due to drug use is not yet been fully under-
stood, significant inhibition of bone remodeling based
on the drug’s pharmacological effect has been considered
to be the main cause [6–8].
After the first report of bisphosphonate-related osteo-
necrosis of the jaw (BRONJ) in 2003 [4], the American
Association of Oral and Maxillofacial Surgeons (AAOMS)
defined BRONJ in their 2009 position paper as “necrotic
bone exposure in the maxillofacial region lasting for more
than 8 weeks in patients with previous or current adminis-
tration of BP and with no history of radiation therapy” [9].
In the latest position paper in 2014, AAOMS modified the
term into medication-related osteonecrosis of the jaw
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(MRONJ) to emphasize the role of drugs causing osteo-
necrosis of the jaw [7]. The incidence of BRONJ has been
reported to be 0.01 to 6.7 % [7]. Considering the world-
wide trend of increasing BP therapy and high BP depend-
ence, the incidence is expected to continuously grow [10].
Although the treatment modalities are not established,
most researchers have recommended conservative ap-
proaches and the additional use of growth factors or
hormone therapy [7, 11].
In 2009, Park et al. [12] reported that only 56.5 % of
Korean dentists were aware of BRONJ, and another study
reported similar awareness in dental hygienists [13]. There-
fore, efforts to increase the awareness of BRONJ among
oral health professionals have been made, emphasizing the
importance of prevention of the disease and research on in-
tractable osteonecrosis of the jaw.
However, there have been few studies on medical doctors’
awareness of BRONJ and how well dental referrals are be-
ing carried out. As in other forms of osteonecrosis, such as
osteoradionecrosis and osteomyelitis of jaw, BRONJ usually
has a poor prognosis and demands long-term treatment,
thus mutual efforts between the medical doctor and dentist
through a multi-disciplinary approach are essential in the
diagnosis, treatment, and prevention of BRONJ [14].
Therefore, this study aimed to investigate the awareness
of BRONJ among medical doctors who prescribe BPs
and the current situation of dental referrals in the
multi-disciplinary treatment and prevention of BRONJ.
Methods
Among 17 tertiary medical institutions in Seoul, Korea
which are registered with the Health Insurance Review
Agency as of July of 2015, 6 were selected based on a
random sampling method. The subjects from the selected
institutions were medical specialists and residents of
internal medicine (endocrinology, rheumatology, oncol-
ogy), family medicine, and orthopedics who agreed to
participate in the study.
The number of subjects was determined to be 172 based
on Cohen’s sample size calculations with a power of more
than 90 % and a significance level of 0.05 (two-sided test).
After accounting for dropouts from the study, a total of
200 subjects were used [15]. The study was carried out by
visiting the participating institutions and distributing self-
administered questionnaires. After thoroughly explaining
the purpose and content of the study, the surveys were
given out to only those who voluntarily chose to partici-
pate in the study. Surveys that were not collected on the
same day of distribution were collected during another
visit to the institutions or were sent through mail. Of the
200 surveys, 192 were used in the analysis after excluding
4 uncollected surveys and 4 surveys with insufficient an-
swers. This study was approved by the Ethics Committee
of Ewha Womans University, Seoul, Korea (15-16B-16).
In the study, the terminology ‘BRONJ’ rather than
‘MRONJ’ or ‘ARONJ’ (antiresorptive-related osteonecrosis
of the jaw) was used. Considering that the target sample
of this survey was medical doctors who do not treat ONJ
themselves and are unfamiliar with the relatively novel
terminology MRONJ, the term BRONJ was preferentially
used. Also, because antiresorptive agents include not only
BP and monoclonal antibodies, but also calcitonin, estro-
gens, and selective estrogen receptor modulators, the
authors considered the terminology BRONJ rather than
ARONJ to be more appropriate for this study.
The survey was comprised of a total of 22 questions.
Personal information was not included. First, the surveys
were categorized according to the specialties: internal
medicine (endocrinology, rheumatology, oncology), family
medicine, and orthopedics. Period of career was divided
into the following: (1) less than 5 years, (2) between 5 and
10 years, (3) between 10 and 20 years, and (4) more than
20 years. Questions regarding BP treatment, the reason for
administration, the doctors’ level of awareness, and dental
examination and referrals were also included in the ques-
tionnaire. (See Additional file 1) The medical doctors’ un-
derstanding of BRONJ was evaluated using the AAOMS
guidelines, consisting of questions regarding the definition,
staging, treatment, and prevention of the disease, and the
discontinuation of BP [7].
Descriptive statistics were utilized for the general
characteristics of samples, BP therapy, experience with
BRONJ patients, and the doctors’ sources on BRONJ
information. For evaluating the degree of understand-
ing, 1 point was given for each correct answer to the
questions regarding the definition, staging, treatment,
prevention, and drug discharge. No points were given
when the subject answered incorrectly or by answering
‘I do not know.’ Higher points correspond to higher
level of understanding. The group differences in level
of understanding were evaluated according to job char-
acteristics, BP indication, administration route, and ex-
perience of BRONJ patients.
For evaluating the degree of dental referrals, the ques-
tion was based on a 5-point scale with answer choices of
‘before’, ‘during’, and ‘after BP administration’. When 100 %
of patients requiring BP administration were being re-
ferred to dentists, 5 points were given, and on the other
hand, when less than 10 % were being referred, 1 point
was given. The reasons for not referring patients to den-
tists were presented, and the group differences of dental
referrals were evaluated according to job characteristics,
BP indication, administration route, doctor’s awareness,
and experience with BRONJ patients.
Statistical analyses were performed using SPSS 20.0
(SPSS Inc., Chicago, IL, USA). Frequency and percentage
analysis, chi-square test, independent sample T-test, and
one-way analysis of variance were performed. For post
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hoc testing, Scheffe’s test was used. All values were con-
sidered statistically significant when P < 0.05.
Results
General characteristics of the 192 surveyed medical
doctors, BP therapy, and experience with BRONJ patients
are summarized in Table 1. In the question regarding
awareness of BRONJ, 150 doctors (78.1 %) answered
“heard of the disease,” and 42 (21.9 %) answered “have not
heard of the disease.” Medical specialists were more aware
of BRONJ compared to residents (P < 0.01), and the high-
est level of awareness was seen in the group with more
than 20 years of work experience, followed by less than
5 years, between 10 and 20 years, and between 5 and
10 years (P < 0.01). On the other hand, there was no sig-
nificant difference between the areas of specialty. The ma-
jority of participants (38 %) responded that the source
from which they acquired awareness of the disease was
academic journals, followed by educational seminars
(30 %), books (20 %), newspapers (5 %), internet (4 %),
and others, such as from colleagues, or patient experi-
ences (3 %).
To determine the level of BRONJ understanding, 5
questions concerning the definition, staging, drug dis-
continuation, prevention, and proper management of the
disease were included. Only 17 doctors (8.9 %) answered
all 5 questions correctly, and 20.9 % (n = 21) received
zero points. Medical specialists had higher scores com-
pared to residents, and the group with 10 to 20 years of
work experience had the highest level of BRONJ know-
ledge (P < 0.01). Also, medical doctors who had experi-
ence with BRONJ patients showed a significantly higher
awareness score.(P < 0.01). However, there was no statis-
tically significant difference in the level of BRONJ know-
ledge between the areas of specialty (P > 0.05; Table 2).
According to the 5-point scale, the degree of dental re-
ferrals for BP administration was 1.86 ± 1.2 before admin-
istration, 1.99 ± 1.2 during administration, and 1.78 ± 1.1
after administration. The results were not significantly dif-
ferent according to the participants’ position and period of
career. On the other hand, based on the areas of specialty,
before BP administration (P < 0.01), during administration
(P < 0.01), and after administration (P < 0.05), all displayed
statistically significant differences with internal medicine
showing the highest degree of dental referrals, followed by
family medicine and orthopedics. Also, the group with
BRONJ awareness and prescribing BP to prevent bone
metastases showed a higher degree of dental referrals (P <
0.01) compared to the group prescribing the drug for
treatment of osteoporosis.
Table 1 General characteristics of surveyed medical doctors,
bisphosphonate (BP) therapy and experience of bisphosphonate-
related osteonecrosis of the jaw (BRONJ) patients (n = 192)
Group N Percent
Position Specialists 114 59.4
Residents 78 40.6
Specialty Family medicine 50 26.1
Orthopedics 55 28.6
Internal Medicine 87 45.3
Period of Career <5 years 69 35.9
5 ~ 10 years 33 17.2
10 ~ 20 years 36 18.8
>20 years 54 28.1
Indications for BP use Osteoporosis 160 83.3
Cancer 31 16.2
Others 1 0.5

















Do not know 24 12.5
Number of patients with
BRONJ (n = 53)
1–3 35 66.0
3–6 16 30.2
Over 6 2 3.8
Table 2 Assessment of Knowledge on bisphosphonate-related
osteonecrosis of the jaw (BRONJ)
BRONJ Knowledge P value
N M± SD
Position Specialist 78 1.99 ± 1.392 .001
Resident 114 2.66 ± 1.314
Period of Career <5 years 69 1.88 ± 1.40 .002
5 ~ 10 years 33 2.45 ± 1.23
10 ~ 20 years 36 2.83 ± 1.38
>20 years 54 2.63 ± 1.31
Specialty Family medicine 50 2.52 ± 1.58 .106
Orthopedics 55 2.04 ± 1.32
Internal medicine 87 2.37 ± 1.39
Experience of
BRONJ patients
Yes 53 3.04 ± 1.34 <0.001
No 139 2.14 ± 1.49
Indications for
use (n = 191)
Osteoporosis 160 2.26 ± 1.319 .009
Cancer 31 2.97 ± 1.602
M mean score of total correct answers on BRONJ
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The perception of the necessity of dental referrals ac-
cording to the areas of specialty was highest in oncology
(4.30 ± 1.08), followed by endocrinology (3.65 ± 0.98),
rheumatology (3.44 ± 1.42), family medicine (3.36 ± 1.22),
and orthopedics (3.12 ± 1.21) (P < .05). However, the degree
of dental referrals did not show a statistically significant
difference among the areas of specialty (P > 0.05). The
reasons for not making dental referrals differed among
the specialties (Fig. 1). In family medicine, endocrin-
ology, and rheumatology, the majority answered that
they did not feel the necessity of dental referrals; in or-
thopedics, it was difficult to earn patient cooperation
due to financial, time, and motivational issues; and in
oncology, they thought that the treatment of systemic
disease was more urgent than dental treatment.
Discussion
Since the first report of BRONJ in 2003, there have been
various clinical and experimental studies, yet much of the
treatment and prognosis of the disease remain unknown
[16]. Considering the refractory progress of BRONJ, it has
widely been accepted that the best measure for BRONJ
treatment is prevention. Therefore it is critical for medical
doctors to implement dental referrals for pre-evaluation of
oral health and dental risk factors before administering
BP [7, 14, 17].
In 2005, the FDA attempted to increase BRONJ
awareness among healthcare providers by adding a
warning statement of possible osteonecrosis of the jaw
through administration of BP. However, in this study,
21.9 % of the medical doctors surveyed had not heard
of the disease, and only 9.9 % correctly answered all 5
questions, indicating a very limited BRONJ awareness.
The knowledge score was significantly higher in doctors
who had experience with BRONJ patients. This could be
due to their efforts to obtain more information relevant to
the cases that they have handled. As a result, the need for
educating those who showed lower scores is paramount
particularly if they have not handled actual cases. Encoun-
tering the development of ONJ before proper education
and through understanding of the disease could lead to
poor medical practice. Considering that knowledge of
BRONJ was acquired mainly through academic journals
(38.5 %) and educational seminars (30.3 %), continuous
educational publications and development of highly ac-
cessible educational programs for medical doctors are
deemed urgent and necessary.
Kholsa et al. [11] and Lam et al. [17] reported that
management of periodontal disease and oral hygiene are
most important in patients who require treatment with
BP, thus emphasizing the necessity of informing them of
the risk of BRONJ and importance of performing dental
treatment before and during drug administration. How-
ever, according to the present study, the percentage of
dental referrals before, during, and after the administra-
tion of BP remains low, in less than 30 % of total patients.
Given the reasons for not making dental referrals accord-
ing to the area of specialty as stated previously, the need
to express the extreme importance for dental examination
and generate a well-coordinated referral system is recom-
mended through open communication and exchange of
expertise from both fields.
Several studies recommended that thorough history
taking, mutual exchange between the dentist and medical
specialist, and providing detailed information of BRONJ to
patients are essential to its prevention [14, 16]. For the pre-
vention of BRONJ, unsalvageable teeth are recommended
Fig. 1 Reasons why medical doctors do not make dental referrals
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to be extracted before starting BP treatment [7, 14].
Also, if all dental procedures are performed prior to BP
administration, future invasive procedures such as dental
extractions can be prevented. Preventive measures for op-
timal oral health can lead to a decrease in the number of
BRONJ patients [7].
A limitation of this study is that the subjects were 192
medical doctors selected through random sampling in ter-
tiary hospitals, therefore the authors cannot declare with
certainty that the sample represents all medical doctors nor
can the authors exclude selection bias. Further studies with
a sufficient sample size and joint research with the other
medical societies would provide more reliable results.
Conclusion
Through this study, it was shown that the medical doctors’
awareness of BRONJ was low. Based on the finding that
only 30 % of patients taking BPs are referred to dentists,
these results are valuable as basic educational data to not
only express the urgency and severity of BRONJ to medical
doctors but to emphasize the utmost importance of preven-
tion through mutual communication between dentists and
medical doctors as well.
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